KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Current Assets (2016 - 2026)

AbbVie has reported Current Assets over the past 14 years, most recently at $29.1 billion for Q4 2025.

  • Quarterly Current Assets rose 13.6% to $29.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.1 billion through Dec 2025, up 13.6% year-over-year, with the annual reading at $29.1 billion for FY2025, 13.6% up from the prior year.
  • Current Assets was $29.1 billion for Q4 2025 at AbbVie, up from $28.5 billion in the prior quarter.
  • Over five years, Current Assets peaked at $38.9 billion in Q1 2024 and troughed at $25.6 billion in Q4 2024.
  • The 5-year median for Current Assets is $28.7 billion (2023), against an average of $29.3 billion.
  • Year-over-year, Current Assets tumbled 48.67% in 2021 and then skyrocketed 46.75% in 2024.
  • A 5-year view of Current Assets shows it stood at $27.9 billion in 2021, then increased by 1.92% to $28.5 billion in 2022, then grew by 15.95% to $33.0 billion in 2023, then dropped by 22.48% to $25.6 billion in 2024, then increased by 13.6% to $29.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Current Assets are $29.1 billion (Q4 2025), $28.5 billion (Q3 2025), and $29.3 billion (Q2 2025).